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To the Editor:  
Exercise-induced bronchoconstriction (EIB) refers to acute airway narrowing that occurs in association 
with physical activity and is prevalent in both elite and recreational athletes 1,2. It is important to 
accurately detect EIB to reduce its potential impact on respiratory health and sporting performance 3 4, 
however diagnosis is clinically challenging due to the limited value of self-reported respiratory 
symptoms 5 and broad differential diagnosis associated with exertional breathing difficulty 6. It is 
therefore recommended that EIB should be objectively confirmed via indirect bronchoprovocation prior 
to initiating treatment 7. In this context, exercise challenge testing (EX) and eucapnic voluntary 
hyperpnoea (EVH) are the most commonly employed diagnostic tests, with a positive result most 
typically defined as a pre-post challenge reduction in lung function; i.e. ≥10% fall in FEV1 7. However, 
the most appropriate diagnostic threshold currently remains unclear on the basis that the ‘normative’ 
airway response to EX appears to be mild bronchodilation (primarily due to withdrawal of vagal 
cholinergic tone) - whereas the highly provocative stimulus of EVH typically elicits 
bronchoconstriction 8. Accordingly, to date, there remains a lack of consensus regarding the optimal or 
‘gold-standard’ approach to assessment 9, which in turn, presents a potential for misdiagnosis; i.e. over 
and under-detection.  
The primary aim of this study was therefore to compare the airway response to EX (conducted in a 
controlled dry environment) against an EVH challenge. An evaluation of current 7 and revised 
diagnostic thresholds 8 was undertaken to determine the impact of any proposed modification to EIB 
screening outcome. We hypothesised that the achieved ventilation and severity of bronchoconstriction 
would be greater following EVH in comparison to EX. 
The study was conducted as a multi-site randomised trial. Following approval from local research ethics 
committees, sixty-three recreationally active individuals (≥5 hours endurance training per week) (male: 
n = 47) provided written informed consent. At the beginning of each visit, exertional respiratory 
symptoms and eosinophilic airway inflammation were assessed via interview and fractional exhaled 
nitric oxide (FeNO), respectively, followed by either an EX or EVH challenge. Spirometry was 
performed in triplicate at baseline and in duplicate at 3, 5, 7, 10, and 15-min post challenge. A positive 
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diagnosis for EIB was defined by ≥10% fall in FEV1 at two consecutive time-points for both EX and 
EVH 7 and  ≥15% fall in FEV1 at one time-point for EVH 8 (for detailed overview of study methodology 
refer to online supplement). 
Fourteen participants (22%) had a prior diagnosis of asthma +/- EIB. Despite this, all participants had 
normal resting lung function with no evidence of airflow limitation (FEV1 predicted >80% and 
FEV1/FVC >70% predicted). Over half of the cohort (63%) reported exertional respiratory symptoms, 
and twenty-six (41%) had elevated FeNO (>25ppb). Clinical characteristics and baseline lung function 
are presented in Table 1. 
Fifty-eight (92%) and forty-four (70%) participants achieved a V̇E ≥60% predicted MVV (i.e. the 
accepted minimal ventilatory load for a valid test) for EVH and EX, respectively. Although power 
output during EX (260 ± 57 W) was lower than the calculated target (323 ± 92 W; P<0.01), all 
participants achieved a mean heart rate >80% predicted maximum (162 ± 11 beats.min-1). Despite this, 
V̇E for EX (93 ± 19 L.min-1) was lower than EVH 106 ± 22 L.min-1, P<0.01; Table 1). 
The mean fall in FEV1 was greater following EVH (-7.9 ± 6.9%) in comparison to EX (-1.9 ± 7.1; 
P<0.01), with a reduction in FEV1 observed following EVH in almost all participants (94%). In contrast, 
EX elicited bronchodilation in over half of the cohort (53%). Thirteen (21%) had a fall in FEV1 ≥10% 
following EVH, of which five (8%) were positive to EX. Importantly, none were positive to EX and 
negative to EVH (Figure 1a). Furthermore, in those with ≥10% fall in FEV1, the mean reduction in lung 
function (i.e. severity of EIB) was greater following EVH (-19 ± 7%) in comparison to EX (-11 ± 9%; 
P<0.01). Nine (14%) had a ≥15% fall in FEV1 post EVH, of which four (6%) were positive to EX. Of 
note, in those who failed to achieve 60% MVV, two were still positive to EVH whereas none were 
positive to EX. Although a positive correlation was observed between EX and EVH (rs = 0.46, p <0.01) 
the mean bias was 6.1% with wide limits of agreement (LOA) (-5.3 to +17.5 %) (Figure 1b). Similarly, 
a positive correlation was observed in those with asthma +/- EIB (r = 0.73, p <0.05) (mean bias: 7.5%; 
LOA: -6.7 to + 22.7%). Importantly, a similar pattern of response was observed for the forty-four 
participants (70%) who achieved ≥60% MVV for both tests. The mean fall in FEV1 was greater 
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following EVH (-8.3 ± 7.4%) in comparison to EX (-2.3 ± 7.8; P<0.01). Eleven (25%) had a fall in 
FEV1 ≥10% following EVH, of which five (18%) were positive to EX. Seven (16%) had a ≥15% fall 
in FEV1 post EVH, of which four (6%) were positive to EX. Sensitivity and specificity for EVH and 
FeNO (to predict a positive EX test) are presented (for the entire cohort) in Tables S2 and S3, 
respectively. 
The present study indicates that the proportion of individuals who meet the diagnostic criteria for EIB 
is consistently greater following EVH in comparison to a controlled laboratory EX test in a standardised 
dry environment. Applying a 10% fall in FEV1 cut-off for EVH increases diagnostic sensitivity, whereas 
a 15% fall in FEV1 improves diagnostic specificity. The observed disparity in screening outcome has 
implications for the clinical application of EVH when utilised as a surrogate airway challenge for EX 
and highlights a potential risk of over and under-detection depending on test selection when applying 
current guidelines 7.  
The airway response to any indirect bronchoprovocation challenge is directly related to the potency of 
the airway stimulus delivered. In the context of EX and EVH, provocation is primarily driven by V̇E 
and the water content of inspired air. However, aligning V̇E for EX and EVH is problematic from a 
methodological standpoint on the basis that V̇E increases over time with EX, whereas EVH involves an 
immediate square-wave rise with sustained hyperpnoea throughout the challenge. In addition, the 
relative humidity of medical-grade gas utilised for EVH was substantially lower (EX: 25% RH vs. 
EVH: 2% RH) despite conducting EX in a controlled environment in accordance with current ATS 
recommendations (<10 mg H2O/L) 7. It is important to highlight that a warm-up prior to EX was 
included in the present study (albeit low intensity without a rest period), and whilst speculative, it is 
possible for a refractory period to have occurred in some participants. Taken together these factors 
likely explain the observed disparity in EIB prevalence between tests (EX: 8% vs. EVH: 21%). Finally, 
although employing a revised threshold for EVH 8 contributed to improved diagnostic agreement (EX: 
8% vs. EVH: 14%) - one participant with a mild positive FEV1 fall post EX (~10%) remained 
undetected. Of note, this individual did not report exertional respiratory symptoms (i.e. entirely 
asymptomatic) and would therefore only be detected via widespread screening.  
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Our findings indicate that the proportion of individuals who meet the diagnostic criteria for EIB is 
consistently greater following EVH in comparison to EX. A pragmatic solution for practitioners 
utilising EVH to screen athletes may be to apply a 10% fall in FEV1 cut-off to ensure no EIB cases are 
missed, whereas a 15% fall in FEV1 cut-off may increase the ‘clinical’ relevance in athletes presenting 
with exertional breathing difficulty. Further population-based research evaluating the normative 
response to indirect bronchoprovocation in this setting remains a priority. 
Anna Jackson* PhD  
Hayden Allen* MRes 
James H. Hull PhD 
Susan H. Backhouse PhD  
James Hopker PhD  
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Table 1. Participant clinical characteristics and airway response to EX and EVH.  
 
Data presented as mean ± SD and ratio (percentage). *Indicates difference between EVH and EX (P<0.05). Non-normally 
distributed data presented as median score (range). Definitions of abbreviations: BMI, body mass index; EVH, eucapnic voluntary 
hyperpnea; EX, exercise challenge test; FEV1, Forced expiratory volume in 1-s; FVC, Forced vital capacity; PEF, Peak expiratory 




Sex (M:F) 47 : 16  
Age (years) 32 ± 11 
Height (cm) 177 ± 11 
Weight (kg) 74 ± 12 
BMI (kgm-2) 24 ± 3 
Training (hrswk-1) 9 ± 4 
Physician diagnosed asthma +/- EIB 14/63 (22%) 
Inhaler therapy: 14/14 (100%) 
     Short-acting beta-2-agonist (SABA) 12/14 (86%) 
     Inhaled corticosteroid (ICS) 1/14 (7%) 
     SABA + ICS 1/14 (7%) 
Exertional respiratory symptoms: 43/63 (67%) 
     Cough 27/63 (43%) 
     Excessive mucus production 22/63 (35%) 
     Wheeze 18/63 (29%) 
     Chest tightness 11/63 (17%) 
     Dyspnoea 9/63 (14%) 
 
EVH EX P-value 
FEV1 (L) 4.07 ± 0.73 4.05 ± 0.73 0.25 
FEV1 predicted (%) 103.9 ± 11.3 103.6 ± 11.1 0.42 
FVC (L) 5.11 ± 1.08 5.10 ± 1.07 0.46 
FVC predicted (%) 108.9 ± 13.0 108.6 ± 13.3 0.53 
FEV1/FVC (%) 80.2 ± 7.2 80.1 ± 6.7 0.70 
PEF (L.min-1) 576.1 ± 93.6 575.7 ± 92.9 0.89 
PEF predicted (%) 107.6 ± 15.3 107.5 ± 15.3 0.86 
Predicted min ventilation (L.min-1) 142 ± 26 142 ± 25 0.28 
Achieved min ventilation (L.min-1) 106 ± 22 93 ± 19 <0.01* 
Achieved min ventilation (%) 75 ± 12 67 ± 16 <0.01* 
Average fall in FEV1 (%) -7.9 ± 6.9 -1.9 ± 7.0 <0.01* 
EIB positive (≥10% fall in FEV1) 13/63 (21%) 5/63 (8%) <0.01* 
EIB positive (≥15% fall in FEV1) 9/63 (14%) 2/63 (2%) <0.01* 
FeNO (ppb) 20 (5-162) 18 (5-155) 0.29 











Figure 1a. Airway response following bronchoprovocation.  
EX + EVH negative (closed circles); EX + EVH positive (open circles); EX negative + EVH positive 
(split circles); EX positive + EVH negative (closed triangle). Diagnostic thresholds: Black vertical line 
and black horizontal line (≥10% fall in FEV1 at two consecutive time-points); Red vertical line (15% 
fall in FEV1 at one time-point).  
 
Figure 1b. Bland-Altman plot of the change in FEV1 post EX and EVH challenges.  
 
